Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2002 Feb;72(2):184–187. doi: 10.1136/jnnp.72.2.184

HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis

A Hensiek 1, S Sawcer 1, R Feakes 1, J Deans 1, A Mander 1, E Akesson 1, R Roxburgh 1, F Coraddu 1, S Smith 1, D Compston 1
PMCID: PMC1737743  PMID: 11796767

Abstract

Background: The association between multiple sclerosis and class II alleles of the major histocompatibiliy complex, in particular the DRB1*1501-DQB1*0602 haplotype, is well established but their role in determining specific features of this clinically heterogeneous disease is unknown as few studies involving large sample sizes have been performed.

Method: 729 patients with multiple sclerosis were typed for the HLA DR15 phenotype. All patients underwent clinical assessment and a detailed evaluation of their clinical records was undertaken.

Results: The presence of DR15 was associated with younger age at diagnosis and female sex but there was no association with disease course (relapsing-remitting or secondary progressive v primary progressive type), disease outcome, specific clinical features (opticospinal v disseminated form), diagnostic certainty (clinically and laboratory supported definite v clinically probable multiple sclerosis), and paraclinical investigations including the presence of oligoclonal bands in the CSF or characteristic abnormalities on MRI imaging of the central nervous system.

Conclusion:Even though DR15 carriers are more likely to be female and prone to an earlier disease onset, the results indicate that there is no association with other specific clinical outcomes or laboratory indices examined here. This suggests that DR15 exerts a susceptibility rather than disease modifying effect in multiple sclerosis.

Full Text

The Full Text of this article is available as a PDF (97.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodmer J. G., Marsh S. G., Albert E. D., Bodmer W. F., Bontrop R. E., Dupont B., Erlich H. A., Hansen J. A., Mach B., Mayr W. R. Nomenclature for factors of the HLA System, 1998. Hum Immunol. 1999 Apr;60(4):361–395. doi: 10.1016/s0198-8859(99)00042-7. [DOI] [PubMed] [Google Scholar]
  2. Brassat D., Azais-Vuillemin C., Yaouanq J., Semana G., Reboul J., Cournu I., Mertens C., Edan G., Lyon-Caen O., Clanet M. Familial factors influence disability in MS multiplex families. French Multiple Sclerosis Genetics Group. Neurology. 1999 May 12;52(8):1632–1636. doi: 10.1212/wnl.52.8.1632. [DOI] [PubMed] [Google Scholar]
  3. Celius E. G., Harbo H. F., Egeland T., Vartdal F., Vandvik B., Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci. 2000 Sep 15;178(2):132–135. doi: 10.1016/s0022-510x(00)00389-0. [DOI] [PubMed] [Google Scholar]
  4. Cocco E., Marrosu M. G. Is multiple sclerosis severity a genetically influenced trait? Neurol Sci. 2000;21(4 Suppl 2):S843–S847. doi: 10.1007/s100720070023. [DOI] [PubMed] [Google Scholar]
  5. Compston D. A., Batchelor J. R., McDonald W. I. B-lymphocyte alloantigens associated with multiple sclerosis. Lancet. 1976 Dec 11;2(7998):1261–1265. doi: 10.1016/s0140-6736(76)92027-4. [DOI] [PubMed] [Google Scholar]
  6. Compston D. A., Kellar Wood H., Robertson N., Sawcer S., Wood N. W. Genes and susceptibility to multiple sclerosis. Acta Neurol Scand Suppl. 1995;161:43–51. doi: 10.1111/j.1600-0404.1995.tb05855.x. [DOI] [PubMed] [Google Scholar]
  7. Coraddu F., Reyes-Yanez M. P., Parra A., Gray J., Smith S. I., Taylor C. J., Compston D. A. HLA associations with multiple sclerosis in the Canary Islands. J Neuroimmunol. 1998 Jul 1;87(1-2):130–135. doi: 10.1016/s0165-5728(98)00074-5. [DOI] [PubMed] [Google Scholar]
  8. Duquette P., Décary F., Pleines J., Boivin D., Lamoureux G., Cosgrove J. B., Lapierre Y. Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression. Can J Neurol Sci. 1985 May;12(2):106–110. doi: 10.1017/s0317167100046795. [DOI] [PubMed] [Google Scholar]
  9. Engell T., Raun N. E., Thomsen M., Platz P. HLA and heterogeneity of multiple sclerosis. Neurology. 1982 Sep;32(9):1043–1046. doi: 10.1212/wnl.32.9.1043. [DOI] [PubMed] [Google Scholar]
  10. Haines J. L., Terwedow H. A., Burgess K., Pericak-Vance M. A., Rimmler J. B., Martin E. R., Oksenberg J. R., Lincoln R., Zhang D. Y., Banatao D. R. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum Mol Genet. 1998 Aug;7(8):1229–1234. doi: 10.1093/hmg/7.8.1229. [DOI] [PubMed] [Google Scholar]
  11. Harding A. E., Sweeney M. G., Miller D. H., Mumford C. J., Kellar-Wood H., Menard D., McDonald W. I., Compston D. A. Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain. 1992 Aug;115(Pt 4):979–989. doi: 10.1093/brain/115.4.979. [DOI] [PubMed] [Google Scholar]
  12. Hauser S. L., Oksenberg J. R., Lincoln R., Garovoy J., Beck R. W., Cole S. R., Moke P. S., Kip K. E., Gal R. L., Long D. T. Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group. Neurology. 2000 May 9;54(9):1859–1861. doi: 10.1212/wnl.54.9.1859. [DOI] [PubMed] [Google Scholar]
  13. Hermans G., Stinissen P., Hauben L., Van den Berg-Loonen E., Raus J., Zhang J. Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals. Ann Neurol. 1997 Jul;42(1):18–27. doi: 10.1002/ana.410420106. [DOI] [PubMed] [Google Scholar]
  14. Hillert J., Grönning M., Nyland H., Link H., Olerup O. An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):887–890. doi: 10.1136/jnnp.55.10.887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jersild C., Fog T., Hansen G. S., Thomsen M., Svejgaard A., Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet. 1973 Dec 1;2(7840):1221–1225. doi: 10.1016/s0140-6736(73)90970-7. [DOI] [PubMed] [Google Scholar]
  16. Kira J., Kanai T., Nishimura Y., Yamasaki K., Matsushita S., Kawano Y., Hasuo K., Tobimatsu S., Kobayashi T. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol. 1996 Oct;40(4):569–574. doi: 10.1002/ana.410400405. [DOI] [PubMed] [Google Scholar]
  17. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  18. Lucchinetti C. F., Brück W., Rodriguez M., Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 1996 Jul;6(3):259–274. doi: 10.1111/j.1750-3639.1996.tb00854.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Madigand M., Oger J. J., Fauchet R., Sabouraud O., Genetet B. HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J Neurol Sci. 1982 Mar;53(3):519–529. doi: 10.1016/0022-510x(82)90248-9. [DOI] [PubMed] [Google Scholar]
  20. Marrosu M. G., Murru M. R., Costa G., Murru R., Muntoni F., Cucca F. DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population. Hum Mol Genet. 1998 Aug;7(8):1235–1237. doi: 10.1093/hmg/7.8.1235. [DOI] [PubMed] [Google Scholar]
  21. Masterman T., Ligers A., Olsson T., Andersson M., Olerup O., Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol. 2000 Aug;48(2):211–219. [PubMed] [Google Scholar]
  22. McDonnell G. V., Mawhinney H., Graham C. A., Hawkins S. A., Middleton D. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. J Neurol Sci. 1999 May 1;165(1):77–83. doi: 10.1016/s0022-510x(99)00084-2. [DOI] [PubMed] [Google Scholar]
  23. Olerup O., Hillert J., Fredrikson S., Olsson T., Kam-Hansen S., Möller E., Carlsson B., Wallin J. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci U S A. 1989 Sep;86(18):7113–7117. doi: 10.1073/pnas.86.18.7113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  25. Runmarker B., Martinsson T., Wahlström J., Andersen O. HLA and prognosis in multiple sclerosis. J Neurol. 1994 May;241(6):385–390. doi: 10.1007/BF02033356. [DOI] [PubMed] [Google Scholar]
  26. Saruhan-Direskeneli G., Esin S., Baykan-Kurt B., Ornek I., Vaughan R., Eraksoy M. HLA-DR and -DQ associations with multiple sclerosis in Turkey. Hum Immunol. 1997 Jun;55(1):59–65. doi: 10.1016/s0198-8859(97)00086-4. [DOI] [PubMed] [Google Scholar]
  27. Sawcer S., Goodfellow P. N., Compston A. The genetic analysis of multiple sclerosis. Trends Genet. 1997 Jun;13(6):234–239. doi: 10.1016/S0168-9525(97)01140-2. [DOI] [PubMed] [Google Scholar]
  28. Sellebjerg F., Jensen J., Madsen H. O., Svejgaard A. HLA DRB1*1501 and intrathecal inflammation in multiple sclerosis. Tissue Antigens. 2000 Apr;55(4):312–318. doi: 10.1034/j.1399-0039.2000.550404.x. [DOI] [PubMed] [Google Scholar]
  29. Stendahl-Brodin L., Link H., Möller E., Norrby E. Genetic basis of multiple sclerosis: HLA antigens, disease progression, and oligoclonal IgG in CSF. Acta Neurol Scand. 1979 Jun;59(6):297–308. doi: 10.1111/j.1600-0404.1979.tb02940.x. [DOI] [PubMed] [Google Scholar]
  30. Thompson A. J., Montalban X., Barkhof F., Brochet B., Filippi M., Miller D. H., Polman C. H., Stevenson V. L., McDonald W. I. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol. 2000 Jun;47(6):831–835. [PubMed] [Google Scholar]
  31. Thompson A. J., Polman C. H., Miller D. H., McDonald W. I., Brochet B., Filippi M Montalban X., De Sá J. Primary progressive multiple sclerosis. Brain. 1997 Jun;120(Pt 6):1085–1096. doi: 10.1093/brain/120.6.1085. [DOI] [PubMed] [Google Scholar]
  32. Weinshenker B. G., Hebrink D., Wingerchuk D. M., Klein C. J., Atkinson E., O'Brien P. C., McMurray C. T. Genetic variants in the tumor necrosis factor receptor 1 gene in patients with MS. Neurology. 1999 Apr 22;52(7):1500–1503. doi: 10.1212/wnl.52.7.1500. [DOI] [PubMed] [Google Scholar]
  33. Weinshenker B. G., Santrach P., Bissonet A. S., McDonnell S. K., Schaid D., Moore S. B., Rodriguez M. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology. 1998 Sep;51(3):742–747. doi: 10.1212/wnl.51.3.742. [DOI] [PubMed] [Google Scholar]
  34. Winchester R., Ebers G., Fu S. M., Espinosa L., Zabriskie J., Kunkel H. G. B-cell alloantigen Ag 7a in multiple sclerosis. Lancet. 1975 Oct 25;2(7939):814–814. doi: 10.1016/s0140-6736(75)80033-x. [DOI] [PubMed] [Google Scholar]
  35. Yamasaki K., Horiuchi I., Minohara M., Kawano Y., Ohyagi Y., Yamada T., Mihara F., Ito H., Nishimura Y., Kira J. HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain. 1999 Sep;122(Pt 9):1689–1696. doi: 10.1093/brain/122.9.1689. [DOI] [PubMed] [Google Scholar]
  36. Zipp F., Weber F., Huber S., Sotgiu S., Czlonkowska A., Holler E., Albert E., Weiss E. H., Wekerle H., Hohlfeld R. Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells. Ann Neurol. 1995 Nov;38(5):723–730. doi: 10.1002/ana.410380506. [DOI] [PubMed] [Google Scholar]
  37. de la Concha E. G., Arroyo R., Crusius J. B., Campillo J. A., Martin C., Varela de Seijas E., Peña A. S., Clavería L. E., Fernandez-Arquero M. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. J Neuroimmunol. 1997 Dec;80(1-2):172–178. doi: 10.1016/s0165-5728(97)00153-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES